3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Injections
17
Cisplatin
15
Carboplatin
15
Oxaliplatin
11
Gemcitabine
11
pembrolizumab
8
Capecitabine
8
toripalimab
7
Paclitaxel
7
Etoposide
7
Cyclophosphamide
7
Pemetrexed
6
Irinotecan
6
Drug Therapy
6
spartalizumab
5
fludarabine
5
camrelizumab
5
Vincristine
5
Radiotherapy
5
Leucovorin
5
tislelizumab
4
apatinib
4
anlotinib
4
Interleukin-2
4
Immune Checkpoint Inhibitors
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Fluorouracil
4
Docetaxel
4
Bevacizumab
4
tremelimumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Clinical Trials, Phase II as Topic
×
Other solid neoplasm
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled